TELO vs. LFCR, VERU, GALT, ACRV, OGI, TRVI, OMER, GLSI, RIGL, and ALIM
Should you be buying Telomir Pharmaceuticals stock or one of its competitors? The main competitors of Telomir Pharmaceuticals include Lifecore Biomedical (LFCR), Veru (VERU), Galectin Therapeutics (GALT), Acrivon Therapeutics (ACRV), Organigram (OGI), Trevi Therapeutics (TRVI), Omeros (OMER), Greenwich LifeSciences (GLSI), Rigel Pharmaceuticals (RIGL), and Alimera Sciences (ALIM). These companies are all part of the "pharmaceutical preparations" industry.
Telomir Pharmaceuticals (NASDAQ:TELO) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.
In the previous week, Lifecore Biomedical had 3 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 6 mentions for Lifecore Biomedical and 3 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 1.09 beat Lifecore Biomedical's score of 0.47 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media.
Lifecore Biomedical received 1 more outperform votes than Telomir Pharmaceuticals when rated by MarketBeat users.
Telomir Pharmaceuticals has higher earnings, but lower revenue than Lifecore Biomedical.
83.4% of Lifecore Biomedical shares are owned by institutional investors. 14.6% of Lifecore Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Lifecore Biomedical has a consensus price target of $9.50, suggesting a potential upside of 64.64%. Given Lifecore Biomedical's higher probable upside, analysts clearly believe Lifecore Biomedical is more favorable than Telomir Pharmaceuticals.
Summary
Lifecore Biomedical beats Telomir Pharmaceuticals on 7 of the 9 factors compared between the two stocks.
Get Telomir Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TELO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Telomir Pharmaceuticals Competitors List
Related Companies and Tools
